Tirzepatide GLP-1 medication may be most effective for weight loss
GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.
Jun 15, 2026
0
7
Endocrinology news
Long naps may increase the risk of chronic liver disease in people with diabetes
People with type 2 diabetes who nap longer than 30 minutes every day, regardless of their sleep patterns at night, increase their risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), according ...
Jun 15, 2026
0
3
Clinical trials suggest GLP-1s may improve fertility in men with obesity
GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago. In fact, the research team found GLP-1s may improve ...
Jun 15, 2026
0
4
Menopausal hormone therapy reduces risk of low bone mineral density by 69%, retrospective study finds
Women on menopausal hormone therapy face a decreased risk of low bone mineral density compared with those not using it, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
Jun 15, 2026
0
4
Visceral fat loss leaves 10-year 'metabolic legacy,' cutting diabetes risk by 28% despite weight regain
Lifestyle-induced loss of visceral fat (and not liver fat, pancreatic fat or subcutaneous fat) may have lasting health benefits years after the end of an intervention, even when body weight is fully regained, according to ...
Jun 14, 2026
0
13
Semaglutide linked to lower bone fracture risk
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine ...
Jun 14, 2026
0
7
Inflation Reduction Act's out-of-pocket cap lowered insulin costs, improved usage for some patients
The Inflation Reduction Act's attempt to improve insulin costs for Medicare beneficiaries—by capping out-of-pocket costs at $35—was associated with lower out-of-pocket costs and increased insulin use, but only for a small ...
Jun 14, 2026
0
3
More than half of those who stop GLP-1s restart within a year, study finds
People prescribed GLP-1 medications are more likely to start and stop than most people assume, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
Jun 14, 2026
0
3
Non-hormone medication addresses menopausal symptoms in women
The first real-world study of the FDA-approved nonhormone treatment fezolinetant found the menopausal medication improved hot flashes, depression and anxiety in women, according to industry-sponsored research presented at ...
Jun 14, 2026
0
4
Sugar-free diets may disrupt the gut microbiome, animal study indicates
Eliminating sugar from your diet may be more detrimental than previously thought, according to an animal study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
Jun 13, 2026
1
35
